-

01:53:24 PM

RPTX Stock News

RPTX - Repare Therapeutics Inc

09/19/23 7:00 AM

Nasdaq : RPTX

conferencesclinical triallow float

Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, today announced it will present initial data from Module 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial in a plenary session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held...

RHEA-AI

neutral

09/06/23 7:00 AM

Nasdaq : RPTX

conferenceslow float

Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Morgan Stanley 21 st Annual Global Healthcare Conference on Wednesday, September 13, 2023, at 11:30 a.m. Eastern Time in New York, NY.

RHEA-AI

neutral

08/09/23 4:05 PM

Nasdaq : RPTX

earningslow float

Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023.. “During the second quarter we made great progress advancing our clinical programs and...

RHEA-AI

neutral

06/08/23 7:00 AM

Nasdaq : RPTX

conferenceslow float

Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 44 th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time in Dana Point,...

RHEA-AI

neutral

06/07/23 4:05 PM

Nasdaq : RPTX

clinical triallow float

Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials

Repare Therapeutics Inc., a leading clinical-stage...

RHEA-AI

neutral

06/06/23 7:00 AM

Nasdaq : RPTX

low float

Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, today announced that data from the ongoing Phase 1/ 2 TRESR clinical trial evaluating camonsertib, a potent and selective oral small molecule inhibitor of ATR, were published in Nature Medicine. The article, entitled“ Camonsertib in DNA damage...

RHEA-AI

neutral

06/02/23 7:00 AM

Nasdaq : RPTX

conferencesclinical triallow float

Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present initial monotherapy data from its Phase 1 MYTHIC clinical trial evaluating RP-6306, as well as to provide early...

RHEA-AI

neutral

05/22/23 7:00 AM

Nasdaq : RPTX

low float

Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Repare Therapeutics Inc.,,, a leading clinical-stage precision oncology company, today announced that, in connection with the appointment of Daniel Belanger as the Company’ s EVP, Human Resources, the Company granted Mr. Belanger an inducement stock option to purchase an aggregate of 240,000 of the Company’ s common shares.

RHEA-AI

very positive

05/09/23 4:05 PM

Nasdaq : RPTX

earningslow float

Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2023.. In addition, we are on track to present initial Phase 1 monotherapy...

RHEA-AI

neutral

04/28/23 4:05 PM

Nasdaq : RPTX

managementlow float

Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board of Directors, effective as of the date of the Company’ s upcoming annual meeting of shareholders in June 2023. In parallel, we are honored to welcome Dr. Molineaux to our Board.

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

RPTX Data

IndustryPharmaceutical Preparation Manufacturing
Websitereparerx.com
Security nameRepare Therapeutics Inc
SectorManufacturing
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Repare Therapeutics Inc

repare therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. its approach integrates insights from several fields of cell biology including dna repair and synthetic lethality. repare’s platform combines a proprietary, high throughput, crispr‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics. the company is backed by leading global healthcare investors including founding investor versant ventures and mpm capital. for additional information, please visit www.reparerx.com.